Paul Maier V - 07 Jun 2023 Form 4 Insider Report for Ambrx Biopharma Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 07 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2023, 16:05:18 UTC
Prior SEC filing: 03 Mar 2023
Next SEC filing: 16 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Sonja Nelson, Attorney-in-Fact for Paul V. Maier

Key filing fact

Paul Maier V filed Form 4 for Ambrx Biopharma Inc. on 09 Jun 2023.

Key facts

This page summarizes Paul Maier V's Form 4 filing for Ambrx Biopharma Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Jun 2023, 16:05.

Change

Previous filing in this sequence was filed on 03 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMAM transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +85,000
Change %
Price: $0.000000
Shares after: 85,000
Date: 07 Jun 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven (7) Ordinary Shares of the Issuer.

Footnote F2

Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting.